1. [Chinese expert consensus of antibody-drug conjugate toxicity management for breast cancer].
- Subjects
- Ado-Trastuzumab Emtansine adverse effects, Ado-Trastuzumab Emtansine therapeutic use, Antibodies, Monoclonal adverse effects, Antibodies, Monoclonal therapeutic use, Camptothecin adverse effects, Consensus, Female, Humans, Neutropenia etiology, Receptor, ErbB-2 metabolism, Trastuzumab adverse effects, Trastuzumab therapeutic use, Ventricular Function, Left, Antineoplastic Agents, Immunological adverse effects, Antineoplastic Agents, Immunological therapeutic use, Breast Neoplasms therapy, Cytotoxins adverse effects, Cytotoxins therapeutic use, Immunoconjugates adverse effects, Immunoconjugates therapeutic use, Triple Negative Breast Neoplasms therapy
- Abstract
As a newly emerged class of anticancer bioagents in the most precise and selectively targeted way, antibody-drug conjugate (ADC) combines the cancer-targeting abilities of monoclonal antibodies with the cytotoxicity potency of payload, delivering highly cytotoxic drug into tumors via 'targeted chemotherapy'. ADC has revolutionized the treatment landscape of human epidermal growth factor receptor 2 positive and triple negative subtypes in breast cancer. Three ADCs have been approved by U. S. Food and Drug Administration with breast cancer indications, including trastuzumab emtansine (T-DM1; also approved in China), trastuzumab deruxtecan (T-DXd, DS-8201) and sacituzumab govitecan (IMMU-132; also approved in China). Antibodies, cytotoxic drug, linker, and conjugation process are implicated in ADC profile, resulting in unique adverse drug reactions and toxicity heterogeneity within ADC class. For example, more attention should be paid to the management of thrombocytopenia, hepatotoxicity, and reductions in left ventricular ejection fraction (LVEF) in patients treated with trastuzumab emtansine; clinical physicians should pay attention to the risk of neutropenia, interstitial lung disease/pneumonitis, and reductions in LVEF when treated with trastuzumab deruxtecan; sacituzumab govitecan most frequently caused neutropenia, anemia and diarrhea requiring close monitor. ADC has generally favorable safety profiles, and dose modifications and/or symptomatic supporting treatment are effective in terms of toxicity management. This consensus aims at providing guidance for clinical oncologists of early detection, regular assessment, timely management and follow-up monitor of ADC-associated adverse reactions/events.
- Published
- 2022
- Full Text
- View/download PDF